LBA45 Overall survival (OS) outcomes from NRG-GY004, a phase III study comparing single-agent olaparib or combination cediranib and olaparib to platinum (Plat) based chemotherapy in recurrent plat…

Overview of attention for article published in Annals of Oncology, October 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news: 4 news outlets

Readers on

mendeley: 5 Mendeley

So far, Altmetric has seen 5 news stories from 4 outlets.

Olaparib Plus Cediranib May Not Provide Survival Benefit in Platinum-Resistant or Refractory Ovarian Cancer

Oncology Nursing News, 21 Mar 2024

Compared with standard-of-care (SOC) chemotherapy, olaparib (Lynparza) plus cediranib did not significantly improve progression-f…

Olaparib/Cediranib Does Not Show Survival Benefit in Advanced Ovarian Cancer

Cancer Network, 16 Mar 2024

The phase 2/3 NRG-GY005 trial assessing olaparib plus dediranib did not improve survival vs standard of care in ovarian cancer.

Olaparib Plus Cediranib Falls Short in All-Comers With Platinum-Resistant or Refractory Ovarian Cancer

OncLive, 16 Mar 2024

Olaparib plus cediranib failed to improve PFS and OS vs chemotherapy in patients with platinum-resistant or -refractory…

Olaparib Does Not Improve OS vs Chemo in Recurrent Platinum-Sensitive Ovarian Cancer

AJMC, 17 Nov 2023

The use of olaparib as a monotherapy or in combination with cediranib did not provide a statistically significance overall…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 1 additional news stories.